Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restore: SAR425899 in NASH
NCT03437720Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- May 2019
- Primary completion
- Aug 2021
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 2 trial of bamadutide in Nonalcoholic steatohepatitis (NASH), sponsored by Sanofi. Planned start May 2019; status: withdrawn.
02
Drugs
bamadutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03437720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437720.